DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.

Author(s): Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, Farber HW, McGoon M, Frost A, Allard M, Despain D, Dufton C, Rubin LJ; ARIES-3 Study Group.

Collaborators: Badesch D, Baran D, Benza RL, Boedefeld R, Carroll J, Chakinala M, Channick R, Elton D, Elwing J, Engel P, Farber H, Feldman J, Foley RJ, Frost A, Gabbay E, Garcia H, Gomberg-Maitland M, Gossage J, Gratnon J, Helmersen D, Hill N, Hsu V, Keogh A, Klapholz M, Klinger J, Landzberg M, Markin C, Mathier M, McGoon M, Mehta S, Michaelson J, Michelakis E, Murali S, Oudiz R, Robbins M, Rosenzweig E, Schilz R, Shapiro S, Swisher J, Tapson V, Waxman A, White J, Zaiman A, Abbott C, Adams L, Andrews M, Barasa D, Beckmannn J, Bomba J, Brady D, Bramante T, Brown K, Camanga D, Conger D, Corrigan C, Coslet S, Culbreth R, Danta I, Dougherty M, Dumont M, Evans S, Fearon Clarke J, Fruitger K, Gabbay E, Gendreau P, Grubbs B, Haney D, Hill W, Hosn R, Houtchens J, James M, Jary C, Jenkins K, Jones C, Karasick L, Keltonic P, Kinninger K, Knechtel J, Larew C, Lawler L, Levato E, Logan C, Mallory Y, Mangold C, Marks J, Maslanka N, Mattessich R, McCloskey D, McCollister D, McGary E, Melegari C, Mituniewicz J, Mulchandani N, Oelschlager K, Pidoux A, Purl H, Rhodes P, Rodriguez-Huertas E, Roessell L, Scovel P, Singh S, Smithson B, Stroud L, Thoma M, Tobin K, Van Dijk J, Verry H, Visnaw K, Webster L, Werff E, Witherspoon F.

Affiliation(s): University of Colorado, 12401 E. 17th Avenue, Aurora, CO 80045, USA. David.Badesch@ucdenver.edu

Publication date & source: 2012, Cardiovasc Ther. , 30(2):93-9

INTRODUCTION: Ambrisentan is an oral, once daily, endothelin receptor antagonist approved for treatment of pulmonary arterial hypertension (PAH). Previous studies of ambrisentan were limited to patients with Group 1 PAH and often excluded patients receiving other pulmonary hypertension (PH) therapies. Aims: ARIES-3 was an open-label study evaluating efficacy and safety of ambrisentan in patients with various PH etiologies and background PH medications. Patients received 5 mg ambrisentan once daily for 24 weeks. The primary endpoint was change from baseline in 6-minute walk distance (6MWD) at week 24. RESULTS: A total of 224 patients with PH due to idiopathic and familial PAH (31%), connective tissue disease (18%), chronic hypoxemia (22%), chronic thromboembolic disease (13%), or other etiologies (16%) were enrolled and 53% of patients received stable background PAH therapies. After 24 weeks of therapy, an increase in 6MWD (+21 m; 95% CI: 12-29) and a decrease in B-type natriuretic peptide (-26%; 95% CI: -34 to -16%) was observed in the overall population compared to baseline; however, increases in 6MWD were not observed in several non-Group 1 PH subpopulations. Peripheral edema, headache, and dyspnea were the most common adverse events. CONCLUSION: This study reconfirms the results of previous placebo-controlled studies, which demonstrate that ambrisentan is well tolerated and provides benefit in patients with PAH. Definitive conclusions regarding the safety and efficacy of ambrisentan in specific non-Group 1 PH etiologies cannot be determined and larger, controlled studies will be necessary to determine the efficacy and safety of ambrisentan in these populations.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017